Form D · Pharmaceuticals
Evergreen Theragnostics Inc.
Springfield, NJ · CIK 0001816034
Offering snapshot reported Aug 18, 2023 · SEC filing
- Reported sold
- $15.5M Offering amount: $15.5M
- Investors reported
- 58 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 15, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 18, 2023 | Initial | $15,461,652 | No comparison | 58 | SEC filing |
| Jun 30, 2020 | Initial | $19,451,937 | No comparison | 76 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-490203
Source: Form D, filed Aug 18, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Gerard Ber | Director |
| James Cook | Director, Executive |
| Enrico De Maria | Director |
| Serge Lyashchenko | Director |
| Victor Paulus | Director |
| Sharon Roded | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
27 Commerce St
Springfield, NJ, 07081
Springfield, NJ, 07081